On February 5, 2020, the Patent Trial and Appeal Board (PTAB) sided with Finnegan client Biogen, upholding a patent covering the blockbuster multiple sclerosis drug Tecfidera®. Mylan Pharmaceuticals challenged the patent in an inter partes review (IPR), but the PTAB stated Mylan failed to show that any of the challenged claims are obvious. This is not the first time Biogen’s patent has been challenged and survived review at the PTAB.
Read the full article here.
